Professors Debate
Faculty and administrators from Yale, Wesleyan, Mizzou, and the University of Chicago discussed last semester’s student protests and their intersection with free speech at a recent Aspen Institute event. In the Atlantic.
Faculty and administrators from Yale, Wesleyan, Mizzou, and the University of Chicago discussed last semester’s student protests and their intersection with free speech at a recent Aspen Institute event. In the Atlantic.
"This assault on free discussion is now commonplace on campus. What can be done? First, university presidents and top administrators must show some intellectual courage," writes Charles Lipson. On Real Clear Politics.
The Federal Department of Labor has awarded North Carolina $8 million for technical skills development. The money will be divided between Wake Tech and James Sprunt Community Colleges. In the Triangle Business Journal.
UNC-Chapel Hill plans to hold a symposium on microaggressions. The event will feature "workshops focusing on responding and positively disrupting microaggressions in teaching/learning and the workplace." On the College Fix
A University of Chicago professor has crafted a five-point plan for restoring free speech on college campuses. On Campus Reform.
Forty-five percent of college graduates say college wasn't worth the cost, according to a Consumer Reports survey. On Forbes.
A new report says students who enroll in 15 credits' worth of classes in their first semester are more likely to graduate than those students who enroll with only 12 credits. On Inside Higher Ed.
A provision of the state budget will reimburse UNC-Chapel Hill $500,000, nearly half of the amount the university was fined for exceeding the out-of-state student cap. On the Civitas Institute.
Of the 11.6 million jobs created after the Great Recession, 11.4 million went to those with a college degree. On CNN Money.
New York University’s medical school has shut down eight studies at its psychiatric research center after discovering violations in a study of an experimental, mind-altering medication. In the New York Times.